Major Payment Reform Program for Cancer Drugs Falls Short

“This is the kind of program that makes sense in theory, and it could have been a win-win-win: a win for patients through lower out-of-pocket expenses with equally effective cancer treatments, a win for practices through preserving financial margins, and a win for payers through a reduction in overall spending,” said the study’s senior author Justin E. Bekelman, MD, director of the Penn Center for Cancer Care Innovation at the Abramson Cancer Center and senior fellow in the Leonard Davis Institute for Health Economics. “But in practice, the program had no measurable effect on either prescription patterns or spending.” Read more at Penn Medicine News